HC Wainwright Has Negative Outlook of ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of ($0.98) for the quarter, down from their prior estimate of ($0.97). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($2.83) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at $0.13 EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($3.16) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at $3.08 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same period in the prior year, the company earned ($1.39) EPS. The business’s quarterly revenue was up 10461.3% compared to the same quarter last year.

A number of other brokerages have also commented on ARWR. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. The Goldman Sachs Group raised their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Chardan Capital lifted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. B. Riley Financial increased their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Trading Up 2.3%

ARWR opened at $63.82 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $76.76. The company’s 50 day moving average price is $67.03 and its two-hundred day moving average price is $45.06. The firm has a market capitalization of $8.94 billion, a price-to-earnings ratio of 41.71 and a beta of 1.21.

Insider Activity

In other news, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. This trade represents a 18.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the transaction, the chief executive officer directly owned 3,792,739 shares in the company, valued at $250,700,047.90. This represents a 0.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 510,836 shares of company stock worth $33,603,060. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Tsfg LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals during the third quarter worth $29,000. First Horizon Corp bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $32,000. Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter worth $34,000. Finally, Salomon & Ludwin LLC bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at $34,000. 62.61% of the stock is currently owned by institutional investors.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.